Literature DB >> 21695287

COMT genetic variants and pain.

Inna Belfer1, S Segall.   

Abstract

Catechol-O-methyltransferase (COMT) metabolizes catechol neurotransmitters dopamine, noradrenaline and adrenaline that are involved in various physiological functions including mood, cognition and stress response. Human pain is closely related to all these functions. The gene encoding the COMT enzyme (COMT) has functional polymorphisms that contribute to the interindividual variability in human pain phenotypes such as pain sensitivity, chronicity, severity and response to pain medicine. This review outlines pain symptoms and syndromes that are affected by COMT functional variation, summarizes findings of genetic association studies and provides critical outlook on reported results. Although the exact mechanism of the effect of COMT on human pain is currently uncertain, it has a clear potential to predict clinical outcomes and identify patients at risk for developing pain conditions. Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695287     DOI: 10.1358/dot.2011.47.6.1611895

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  26 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

2.  Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.

Authors:  Steven Z George; Roland Staud; Paul A Borsa; Samuel S Wu; Margaret R Wallace; Warren H Greenfield; Lauren N Mackie; Roger B Fillingim
Journal:  Contemp Clin Trials       Date:  2017-03-14       Impact factor: 2.226

Review 3.  Genetic basis of pain variability: recent advances.

Authors:  Erin E Young; William R Lariviere; Inna Belfer
Journal:  J Med Genet       Date:  2011-11-05       Impact factor: 6.318

4.  The design and methods of genetic studies on acute and chronic postoperative pain in patients after total knee replacement.

Authors:  Inna Belfer; Carol M Greco; Anna Lokshin; Katie Vulakovich; Douglas Landsittel; Feng Dai; Lawrence Crossett; Jacques E Chelly
Journal:  Pain Med       Date:  2014-07-08       Impact factor: 3.750

5.  Heritability of nociception IV: neuropathic pain assays are genetically distinct across methods of peripheral nerve injury.

Authors:  Erin E Young; Michael Costigan; Teri A Herbert; William R Lariviere
Journal:  Pain       Date:  2013-09-24       Impact factor: 6.961

6.  Translating the human genome to manage pediatric postoperative pain.

Authors:  Renee C B Manworren; Gualberto Ruaño; Erin Young; Barbara St Marie; Jacqueline M McGrath
Journal:  J Pediatr Surg Nurs       Date:  2015 Jan-Mar

Review 7.  Janus molecule I: dichotomous effects of COMT in neuropathic vs nociceptive pain modalities.

Authors:  S K Segall; W Maixner; I Belfer; T Wiltshire; Z Seltzer; L Diatchenko
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-05       Impact factor: 4.388

Review 8.  Managing Chronic Pain in Special Populations with Emphasis on Pediatric, Geriatric, and Drug Abuser Populations.

Authors:  Kyle M Baumbauer; Erin E Young; Angela R Starkweather; Jessica W Guite; Beth S Russell; Renee C B Manworren
Journal:  Med Clin North Am       Date:  2016-01       Impact factor: 5.456

9.  Pain modality- and sex-specific effects of COMT genetic functional variants.

Authors:  Inna Belfer; Samantha K Segall; William R Lariviere; Shad B Smith; Feng Dai; Gary D Slade; Naim U Rashid; Jeffrey S Mogil; Claudia M Campbell; Robert R Edwards; Qian Liu; Eric Bair; William Maixner; Luda Diatchenko
Journal:  Pain       Date:  2013-04-17       Impact factor: 6.961

10.  Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors.

Authors:  Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon
Journal:  Support Care Cancer       Date:  2018-10-20       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.